Scancell Holdings plc (FRA:SCP)

Market Cap	158.78M +33.4%
Revenue (ttm)	5.36M
Net Income	-6.28M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	124
Open	0.1190
Previous Close	0.1130
Day's Range	0.1190 - 0.1190
52-Week Range	0.0550 - 0.1490
Beta	n/a
RSI	54.50
Earnings Date	Jan 23, 2026

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 60
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SCP

Financial Performance

Financial numbers in GBP